GlassScriptPhysician profile
Hasan Syed
NPI 1073141420
$2,204.45
in general payments reported to CMS, 2019-2025
25 companies · $776 in 2025
The $776 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $164 · 2024: $1,264 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,204.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $356.17 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $328.42 | 2023-2025 | Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $293.47 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $261.59 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $128.96 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.29 | 2023-2025 | Jardiance |
| Pfizer INC. | $97.66 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.55 | 2024-2025 | |
| Astellas Pharma US INC | $83.49 | 2024-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $51.69 | 2024 | Spravato |
| Dexcom, INC. | $44.92 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $42.08 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $38.39 | 2023-2024 | Quviviq |
| Antares Pharma, INC. | $37.05 | 2024 | Xyosted |
| Lundbeck LLC | $36.07 | 2023-2025 | Vyepti, Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $25.17 | 2024 | Auvelity |
| Eisai INC. | $25.17 | 2024 | |
| Mayne Pharma Commercial LLC | $24.75 | 2025 | |
| Sandoz INC. | $23.46 | 2024 | |
| Seqirus USA INC | $20.28 | 2025 | Flucelvax, Fluad |
| Merck Sharp & Dohme LLC | $18.77 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Dynavax Technologies Corporation | $18.07 | 2025 | Heplisav-B |
| Amgen INC. | $17.57 | 2024 | Krystexxa |
| Amneal Pharmaceuticals LLC | $13.90 | 2024 | Unithroid |
| Sanofi Pasteur INC. | $13.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hasan Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.